ArticleVaccines2021
Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Modeling of longitudinal immune profiles reveals distinct immunogenic signatures following five COVID-19 vaccinations among people living with HIV.Patterns (New York, N.Y.) · 2026Article
- Article
- Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patients.PLoS computational biology · 2025Article
- Mechanistic models of humoral kinetics following COVID-19 vaccination.Journal of the Royal Society, Interface · 2025Article
- A stochastic approach for co-evolution process of virus and human immune system.Scientific reports · 2024Article
- SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series.Scientific reports · 2024Article
- Within-host evolution of SARS-CoV-2: how often areVirus evolution · 2024Article
- Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV.iScience · 2023Article
- A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection.JCI insight · 2023Article
- Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV.bioRxiv : the preprint server for biology · 2023Article
- Monkeypox: a review of epidemiological modelling studies and how modelling has led to mechanistic insight.Epidemiology and infection · 2023Review
- Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: Parameter estimates, identifiability, sensitivity and the eclipse phase profile.Journal of theoretical biology · 2023Article
- A mathematical model of protein subunits COVID-19 vaccines.Mathematical biosciences · 2023Article
- The race to understand immunopathology in COVID-19: Perspectives on the impact of quantitative approaches to understand within-host interactions.Immunoinformatics (Amsterdam, Netherlands) · 2023Review
- A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination.Journal of theoretical biology · 2023Article
- A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA.PloS one · 2023Article
- Plasma SARS-CoV-2 RNA elimination and RAGE kinetics distinguish COVID-19 severity.Clinical & translational immunology · 2023Article
- Article
- Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex.Scientific reports · 2022Article
- Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the SARS-CoV-2 global pandemic, several vaccines, including mRNA and adenovirus vector approaches, have received emergency or full approval. However, supply chain logistics have hampered global vaccine delivery, which is impacting mass vaccination strategies. Recent studies have identified different strategies for vaccine dose administration so that supply constraints issues are diminished. These include increasing the time between consecutive doses in a two-dose vaccine regimen and reducing the dosage of the second dose. We consider both of these strategies in a mathematical modeling study of a non-replicating viral vector adenovirus vaccine in this work. We investigate the impact of different prime-boost strategies by quantifying their effects on immunological outcomes based on simple system of ordinary differential equations. The boost dose is administered either at a standard dose (SD) of 1000 or at a low dose (LD) of 500 or 250 vaccine particles. Results show dose-dependent immune response activity. Our model predictions show that by stretching the prime-boost interval to 18 or 20, in an SD/SD or SD/LD regimen, the minimum promoted antibody (Nab) response will be comparable with the neutralizing antibody level measured in COVID-19 recovered patients. Results also show that the minimum stimulated antibody in SD/SD regimen is identical with the high level observed in clinical trial data. We conclude that an SD/LD regimen may provide protective capacity, which will allow for conservation of vaccine doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.